A review of the clinical efficacy and tolerability of almotriptan in acute migraine

David W. Dodick

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations


Almotriptan is a serotonin (5-hydroxytryptamine, 5-HT)1B/1D-receptor agonist approved for the acute treatment of migraine. In 3500 acute migraine patients enrolled in short-term trials and 1500 patients in long-term open-label trials, almotriptan 12.5 mg was effective and well-tolerated. Almotriptan maintains a consistency of response across three attacks and patients continue to respond to almotriptan for up to 1 year. Results from two comparative studies and a meta-analysis of 53 randomised, placebo-controlled studies of oral triptans in > 24,000 patients, confirm that almotriptan 12.5 mg demonstrates comparable efficacy with sumatriptan 50 and 100 mg. The incidence of treatment-related adverse events with almotriptan is comparable to that of placebo and significantly lower than that with sumatriptan. Drug-drug interaction studies indicate that almotriptan may be coadministered with other commonly prescribed drugs without dose modification. Almotriptan can be recommended as first-line treatment for acute migraine.

Original languageEnglish (US)
Pages (from-to)1157-1163
Number of pages7
JournalExpert Opinion on Pharmacotherapy
Issue number7
StatePublished - Jul 1 2003


  • Adverse events
  • Almotriptan
  • Efficacy
  • Migraine
  • Triptans

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'A review of the clinical efficacy and tolerability of almotriptan in acute migraine'. Together they form a unique fingerprint.

Cite this